K-163-SZ Phase2 placebo-controlled study
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2018
At a glance
- Drugs Pyridoxamine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kowa
- 22 Aug 2018 Planned End Date changed from 30 Nov 2018 to 30 Nov 2019.
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.
- 21 Nov 2017 New trial record